One major cloud that has been hanging over AbbVie (NYSE:ABBV) is how long the company will be able to hold off biosimilar competition for its top-selling drug Humira. Amgen (NASDAQ:AMGN) won FDA approval last year for Amjevita, its biosimilar to Humira. However, Amjevita hasn’t reached the market yet due to AbbVie’s legal challenges.
